6/29/23, 1:44 AM Prednisone in RIF Pathway Feedback Search Clinical Topics Home Studies Prednisone in RIF Prednisone in RIF Trial question What is the role of prednisone in patients with recurrent implantation failure undergoing IVF? Study design Multi-center Double blinded RCT Population 715 female patients Inclusion criteria: women who have undergone 2 embryo transfer cycles with good-quality embryos without achieving a clinical pregnancy Key exclusion criteria: autoimmune diseases; receipt of corticosteroids or immunosuppression medications; diagnosed diseases affecting the cavity; history of recurrent pregnancy loss Interventions N=357 prednisone (an oral dose of 10 mg/day) N=358 placebo (matching placebo once daily) Primary outcome Live birth 38.8 % 38.8 37.8 29.1 % 19.4 % 9.7 % No significant difference 0.0 % Prednisone Placebo No significant difference in live birth (37.8% vs. 38.8%; RR 0.97, 95% CI 0.81 to 1.17) Secondary outcomes Significant increase in biochemical pregnancy loss (17.3% vs. 9.9%; RR 1.75, 95% CI 1.03 to 2.99) https://web.pathway.md/studies/rec1cpyAkwZ5eZnjj 1/2 6/29/23, 1:44 AM Prednisone in RIF Pathway No significant difference in biochemical pregnancy (54.9% vs. 50.8%; RR 1.08, 95% CI 0.94 to 1.24) No significant difference in implantation (42.5% vs. 40.4%; RR 1.05, 95% CI 0.9 to 1.24) Safety outcomes No significant differences in neonatal complications, congenital anomalies, other adverse events. Significant difference in preterm delivery (11.8% vs. 5.5%). Conclusion In women who have undergone 2 embryo transfer cycles with good-quality embryos without achieving a clinical pregnancy, prednisone was not superior to placebo with respect to live birth. Reference Yun Sun, Linlin Cui, Yao Lu et al. Prednisone vs Placebo and Live Birth in Patients With Recurrent Implantation Failure Undergoing In Vitro Fertilization: A Randomized Clinical Trial. JAMA. 2023 May 2;329(17):1460-1468. Open reference URL https://web.pathway.md/studies/rec1cpyAkwZ5eZnjj 2/2